ArticleMolecular biology reports2025
Effects of atranorin on the proliferation, apoptosis and metastasis of two different gastric cancer cell lines and exploring underlying mechanisms.
Article in Molecular biology reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGastric cancer is the fifth most prevalent malignancy worldwide. Atranorin is a polyphenol with significant anti-tumor activities. This study was conducted to evaluate the effect of atranorin on proliferation, apoptosis, and metastasis in two different human gastric cancer cell lines, AGS and HGC-27.
methodsThe anti-proliferative and anti-migration effects of atranorin were evaluated using the MTT and scratch assays, respectively. The expression of apoptosis-related markers, including caspase 3, caspase 9, caspase 8, Bax, and Bcl2, and metastasis markers, including E-cadherin, N-cadherin, vimentin, fibronectin 1, and VEGFA, was quantified at the mRNA and protein levels via quantitative real-time PCR (qRT-PCR) and Western blotting, respectively.
resultsFollowing exposure to varying concentrations of atranorin for 48 and 72 h, both cell lines exhibited a significant, dose-dependent decrease in cell proliferation compared with control groups. Atranorin treatment significantly increased the expression of caspase 3, caspase 9, and Bax in the HGC-27 cell line; conversely, no significant alterations were observed in the expression of caspase 8 and BCL2. In the AGS cell line, atranorin treatment did not significantly affect the expression of apoptosis markers. Atranorin induced apoptosis and inhibited migration in HGC-27 cells. Moreover, atranorin significantly upregulated E-cadherin and downregulated N-cadherin, vimentin, fibronectin 1, and VEGFA.
conclusionAtranorin inhibits proliferation in HGC-27 and AGS cells, induces intrinsic apoptosis, and inhibits metastasis in HGC-27 cells, suggesting its potential as a drug candidate, particularly for targeting metastasis and inducing apoptosis in highly metastatic HGC-27 cells.
Indexed as
Identifiers
41329427What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.